Content Details
H.R. 938 (RH) - Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019
- Category
- Bills and Statutes
- Collection
- Congressional Bills
- SuDoc Class Number
- Y 1.6:
Y 1.4/6:
- Congress Number
- 116th Congress
- Congress Session
- 1st Session
- Last Action Date Listed
- May 2, 2019
- Actions
- Mr. Schrader (for himself and Mr. Carter of Georgia) introduced the following bill; which was referred to the Committee on Energy and Commerce, Additional sponsors: Mrs. Craig, Mrs. Dingell, Mr. Ruiz, Mr. Pallone, Ms. Eshoo, Mr. Kennedy, Ms. Matsui, Mr. Rush, Mr. Van Drew, Ms. Clarke of New York, Mr. Walden, Ms. Schakowsky, Mr. McAdams, Ms. Mucarsel- Powell, and Mr. Meadows, Committed to the Committee of the Whole House on the State of the Union and ordered to be printed
- Bill Number
- H.R. 938
- Bill Version
- Reported in House (RH)
- Short Title
- Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019
- Full Title
- To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
- Sponsors
- Kurt Schrader(OR)
- Cosponsors
- Earl L. "Buddy" Carter (GA); Angie Craig (MN); Debbie Dingell (MI); Raul Ruiz (CA); Frank Pallone, Jr. (NJ); Anna G. Eshoo (CA); Joseph P. Kennedy III (MA); Doris O. Matsui (CA); Bobby L. Rush (IL); Jefferson Van Drew (NJ); Yvette D. Clarke (NY); Greg Walden (OR); Janice D. Schakowsky (IL); Ben McAdams (UT); Debbie Mucarsel-Powell (FL); Mark Meadows (NC)
- Committees
- Committee on Energy and Commerce (Standing)
- Report Number
- H. Rept.116-46
- United States Code Reference
- 21 U.S.C. 355(j)(5)(B)(iv)
Loading...
Loading...